Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Celgene Corporation.

Oncology Consultations®: Discussing the Nurse's Role in Treating and Managing Advanced Pancreatic Adenocarcinoma


Release Date: September 28, 2018
Expiration Date: September 28, 2019
Media: Internet - based

 

Activity Overview

This activity, Oncology Consultations®: Discussing the Nurse’s Role in Treating and Managing Advanced Pancreatic Adenocarcinoma, developed in Physicians’ Education Resource, LLC, (PER®) established Oncology Consultations legacy format, focuses on case-based discussion to optimize treatment for patients with pancreatic cancer. This presentation features Dr. Tanios Bekaii-Saab and Dr. Kelley Rone, providing expert viewpoints on the options for pancreatic cancer treatment, with a focus on the role of the nurse in guiding patients through all aspects of treatment and management: from understanding the diagnosis, to managing side effects of treatment, to potentially participating in clinical trials. Throughout this activity, the experts will discuss treatment decision-making and communicating with the patient, framed by the context of 2 patient cases of pancreatic cancer.

Benefits of Participating

  • Follow a case-based discussion of current and emerging treatment options for pancreatic cancer across the spectrum of disease
  • Gain further insight into the critical role of the nurse in improving patient care by incorporating the multidisciplinary team and managing adverse events related to treatment
  • Increase understanding of the most recent data on current and emerging systemic treatment options for pancreatic cancer

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Celgene Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video Files” will be available for your reference.
  • To receive a CME/CE certificate, participants must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This activity is directed toward medical oncologists, surgical oncologists, nurses, advanced practitioners, and other healthcare professionals who treat and manage patients with metastatic pancreatic cancer.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Detail current approaches to treat pancreatic cancer, including chemotherapeutic, as well as surgical and radiological approaches.
  2. Review the results of recent clinical trials and evaluate their potential to change clinical practice, as well as the potential implications of ongoing and recruiting trials.
  3. Describe major treatment-associated toxicities associated with pancreatic cancer treatment, including strategies for their management to optimize clinical outcomes and quality of life
  4. Delineate the role of oncologists to engage multidisciplinary teams to mitigate the impact of treatment-related adverse events, ensure patient engagement, and improve outcomes through a team-based treatment approach.

Faculty, Staff, and Planners' Disclosures

Faculty

Tanios Bekaii-Saab
Tanios Bekaii-Saab, MD, FACP
Program Co-Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Professor, Mayo Clinic College of Medicine and Science
Senior Associate Consultant
Division of Hematology and Oncology
Mayo Clinic
Phoenix, AZ

Disclosure: Consultant: Merck, Armo BioSciences

Kelley A. Rone
Kelley A. Rone, DNP, AGNP-s
Advanced Practice Nurse, GI Oncology
Division of Hematology and Oncology
Mayo Clinic
Phoenix, AZ

Disclosure: Dr. Kelley Rone has no relevant financial relationships to disclose.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse™ Recaps

1 of 3
Insights from Tanios Bekaii-Saab, MD, FACP, and Kelley Rone, DNP, AGNP-C — PER Pulse™ Recap:
Oncology Consultations®: Discussing the Nurse’s Role in Treating and Managing Advanced Pancreatic Adenocarcinoma

The online continuing medical education activity Oncology Consultations®: Discussing the Nurse’s Role in Treating and Managing Advanced Pancreatic Adenocarcinoma focuses on case-based discussion to optimize treatment for patients with pancreatic cancer. This presentation features Dr. Tanios Bekaii-Saab and Dr. Kelley Rone, who provide expert viewpoints on the options for pancreatic cancer treatment, with a focus on the role of the nurse in guiding patients through all aspects of treatment and management: from understanding the diagnosis, to managing adverse effects of treatment, to potentially participating in clinical trials. Throughout this activity, they will discuss treatment decision making and communicating with the patient, framed by the context of 2 patient cases of pancreatic cancer.

This first of 3 PER Pulse™ Recaps for the activity will focus on a case-based view of borderline resectable pancreatic cancer from diagnosis to staging, and treatment.

Below are some highlights from the activity featuring Dr. Bekaii-Saab, program co-leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center, Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, and Dr. Rone, advanced practice nurse, GI Oncology, Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona:

  • Dr. Bekaii-Saab describes the first case, a patient with borderline resectable pancreatic cancer, and walks through the initial steps in diagnostics and treatment.
  • Dr. Rone provides the nurse’s perspective on counseling patients about their diagnosis and treatment options and coordinating patient care with the medical team.
  • Drs. Bekaii-Saab and Rone discuss the range of treatment choices in neoadjuvant chemotherapy, surgical intervention, and adjuvant therapy for resectable and borderline resectable pancreatic cancer.
  • Dr. Rone elaborates on the nurse’s role in managing adverse events and incorporating other medical professionals, such as dietitians and pharmacists, to improve patient quality of life and treatment compliance.

2 of 3
Insights from Tanios Bekaii-Saab, MD, FACP, and Kelley Rone, DNP, AGNP-C — PER Pulse™ Recap:
Oncology Consultations®: Discussing the Nurse’s Role in Treating and Managing Advanced Pancreatic Adenocarcinoma

As a follow-up to the online continuing medical education activity Oncology Consultations®: Discussing the Nurse’s Role in Treating and Managing Advanced Pancreatic Adenocarcinoma, this second of 3 PER Pulse™ Recaps for the activity will focus on evolving options for patients with borderline resectable disease and how to optimize outcomes for patients with metastatic pancreatic cancer.

Below are some highlights from the activity featuring Dr. Bekaii-Saab, program co-leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center, Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, and Dr. Rone, advanced practice nurse, GI Oncology, Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona:

  • Drs. Bekaii-Saab and Rone discuss the range of treatment choices in neoadjuvant chemotherapy, surgical intervention, and adjuvant therapy for resectable and borderline resectable pancreatic cancer.
  • Dr. Rone elaborates on the nurse’s role in managing adverse events and incorporating other medical professionals, such as dietitians and pharmacists, to improve patient quality of life and treatment compliance.
  • Dr. Bekaii-Saab presents the second patient case, a single mother with metastatic pancreatic cancer. Then Drs. Rone and Bekaii-Saab discuss including a social worker on the care team and incorporating palliative care early in the treatment plan.
  • Dr. Bekaii-Saab reviews the treatment options for patients with metastatic disease and the reasons this patient chose to initiate nab-paclitaxel/gemcitabine as the first line of therapy.

3 of 3
Insights from Tanios Bekaii-Saab, MD, FACP, and Kelley Rone, DNP, AGNP-C — PER Pulse™ Recap:
Oncology Consultations®: Discussing the Nurse’s Role in Treating and Managing Advanced Pancreatic Adenocarcinoma

As a follow-up to the online continuing medical education activity Oncology Consultations®: Discussing the Nurse’s Role in Treating and Managing Advanced Pancreatic Adenocarcinoma, this third of 3 PER Pulse™ Recaps for the activity will focus on the future of advances and emerging options for pancreatic cancer.

Below are some highlights from the activity featuring Dr. Bekaii-Saab, program co-leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center, Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, and Dr. Rone, advanced practice nurse, GI Oncology, Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona:

  • Drs. Rone and Bekaii-Saab discuss how to help patients with metastatic pancreatic cancer understand the options for treatment and whether enrolling in a clinical trial is an appropriate option for them.
  • Dr. Bekaii-Saab reviews recent clinical trial data and recently completed trials likely to report data in the near future.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
2728293031
Filter By